查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1879287

超越傳統藥丸市場－全球產業規模、佔有率、趨勢、機會及預測，依治療領域、產品、地區及競爭格局分類，2020-2030年預測

Beyond The Pill Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Area, By Offerings, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球「超越藥物療法」市場規模將從2024年的2.8244億美元成長到2030年的4.1644億美元，複合年成長率達6.69%。該市場涵蓋創新數位健康解決方案、服務和智慧設備，旨在超越傳統藥物干預，提升患者參與度、治療依從性和整體健康效果。推動該市場擴張的關鍵因素包括：全球慢性病盛行率不斷上升，需要持續管理；對個人化醫療干預的需求日益成長；以及遠端監測和人工智慧等領域的持續技術進步。

市場概覽
預測期 2026-2030
2024年市場規模 2.8244億美元
2030年市場規模 4.1644億美元
2025-2030年複合年成長率 6.69%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球避孕藥市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療領域（糖尿病、腫瘤、心血管疾病、氣喘、其他）
    • 按服務項目（服務、監測、援助、資訊、教育）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美避孕藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲避孕藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區避孕藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲避孕藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲避孕藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球避孕藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
  • Otsuka Pharmaceutical Co., Ltd.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Sanofi SA
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc.
  • Teva Pharmaceutical Industries Ltd.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 8071

The Global Beyond The Pill Market will grow from USD 282.44 Million in 2024 to USD 416.44 Million by 2030 at a 6.69% CAGR. The "Global Beyond The Pill Market" encompasses innovative digital health solutions, services, and smart devices that extend beyond traditional pharmaceutical interventions to enhance patient engagement, treatment adherence, and overall health outcomes. Key drivers supporting this market's expansion include the increasing global prevalence of chronic diseases demanding continuous management, a growing imperative for personalized healthcare interventions, and continuous technological advancements in areas like remote monitoring and artificial intelligence.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 282.44 Million
Market Size 2030USD 416.44 Million
CAGR 2025-20306.69%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

The increasing global burden of chronic diseases represents a primary impetus for the expansion of the "Global Beyond The Pill Market." As populations age and lifestyles evolve, conditions such as diabetes, cardiovascular disease, and chronic respiratory illnesses necessitate continuous management beyond traditional episodic care. These long-term conditions demand solutions that support patient adherence, facilitate remote monitoring, and enable personalized interventions, thereby moving healthcare delivery beyond solely pharmaceutical products. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2025, approximately 589 million adults are living with diabetes worldwide, underscoring the immense and growing patient pool requiring innovative, integrated care models. This persistent and escalating prevalence drives the need for digital health solutions that can effectively integrate into daily life, offering sustained support and improving long-term health outcomes.

Key Market Challenges

The complex and often fragmented global regulatory landscape represents a significant impediment to the growth of the "Global Beyond The Pill Market". This challenge manifests as increased costs and protracted timelines for product development and market access, directly hindering the widespread adoption of innovative digital health solutions. Manufacturers must navigate disparate national and regional requirements, leading to duplicative efforts in testing, documentation, and approval processes.

The financial burden imposed by these regulatory complexities is substantial. According to a MedTech Europe 2024 Regulatory Survey, medical device manufacturers anticipate a 50% increase in maintenance and re-certification costs over a five-year cycle due to evolving regulations. This escalation in operational expenses diminishes investment capacity for research and development into new digital health technologies, effectively slowing the pace of innovation.

Key Market Trends

Strategic Expansion into Solution Provider Models is fundamentally reshaping the "Global Beyond The Pill Market" by shifting the industry focus from standalone product sales to comprehensive, integrated digital health solutions. This trend involves medical technology companies developing ecosystems of devices, software, and supportive services to provide holistic patient management rather than episodic care. According to MedTech Europe's "Facts & Figures 2025" published in September 2025, digital health is rapidly scaling in Europe, driven by a convergence of breakthrough technologies, patient empowerment, and systemic efficiencies within the medical technology sector. This broader strategic emphasis enhances patient engagement and offers continuous support, transforming value creation in healthcare.

Key Market Players

  • F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
  • Otsuka Pharmaceutical Co., Ltd.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc.
  • Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Beyond The Pill Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Beyond The Pill Market , By Therapeutic Area:

  • Diabetes
  • Oncology
  • Cardiovascular Diseases
  • Asthma
  • Others

Beyond The Pill Market , By Offerings:

  • Services
  • Monitoring
  • Assistance
  • Information
  • Education

Beyond The Pill Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Beyond The Pill Market .

Available Customizations:

Global Beyond The Pill Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Beyond The Pill Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Area (Diabetes, Oncology, Cardiovascular Diseases, Asthma, Others)
    • 5.2.2. By Offerings (Services, Monitoring, Assistance, Information, Education)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Beyond The Pill Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Area
    • 6.2.2. By Offerings
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Beyond The Pill Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Area
        • 6.3.1.2.2. By Offerings
    • 6.3.2. Canada Beyond The Pill Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Area
        • 6.3.2.2.2. By Offerings
    • 6.3.3. Mexico Beyond The Pill Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Area
        • 6.3.3.2.2. By Offerings

7. Europe Beyond The Pill Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Area
    • 7.2.2. By Offerings
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Beyond The Pill Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Area
        • 7.3.1.2.2. By Offerings
    • 7.3.2. France Beyond The Pill Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Area
        • 7.3.2.2.2. By Offerings
    • 7.3.3. United Kingdom Beyond The Pill Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Area
        • 7.3.3.2.2. By Offerings
    • 7.3.4. Italy Beyond The Pill Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Area
        • 7.3.4.2.2. By Offerings
    • 7.3.5. Spain Beyond The Pill Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Area
        • 7.3.5.2.2. By Offerings

8. Asia Pacific Beyond The Pill Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Area
    • 8.2.2. By Offerings
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Beyond The Pill Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Area
        • 8.3.1.2.2. By Offerings
    • 8.3.2. India Beyond The Pill Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Area
        • 8.3.2.2.2. By Offerings
    • 8.3.3. Japan Beyond The Pill Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Area
        • 8.3.3.2.2. By Offerings
    • 8.3.4. South Korea Beyond The Pill Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Area
        • 8.3.4.2.2. By Offerings
    • 8.3.5. Australia Beyond The Pill Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Area
        • 8.3.5.2.2. By Offerings

9. Middle East & Africa Beyond The Pill Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Area
    • 9.2.2. By Offerings
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Beyond The Pill Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Area
        • 9.3.1.2.2. By Offerings
    • 9.3.2. UAE Beyond The Pill Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Area
        • 9.3.2.2.2. By Offerings
    • 9.3.3. South Africa Beyond The Pill Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Area
        • 9.3.3.2.2. By Offerings

10. South America Beyond The Pill Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Area
    • 10.2.2. By Offerings
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Beyond The Pill Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Area
        • 10.3.1.2.2. By Offerings
    • 10.3.2. Colombia Beyond The Pill Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Area
        • 10.3.2.2.2. By Offerings
    • 10.3.3. Argentina Beyond The Pill Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Area
        • 10.3.3.2.2. By Offerings

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Beyond The Pill Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd. (Flatiron Health, Inc.)
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Otsuka Pharmaceutical Co., Ltd.
  • 15.3. Amgen, Inc.
  • 15.4. AstraZeneca PLC
  • 15.5. Novartis AG
  • 15.6. Sanofi S.A.
  • 15.7. Novo Nordisk A/S
  • 15.8. Eli Lilly and Company
  • 15.9. Johnson & Johnson Services Inc.
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer